Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Laboratory testing for prothrombotic states: clinical utility.

Michael Greaves1, H G Watson

  • 1Department of Medicine and Therapeutics, University of Aberdeen, Polwarth-Forresterhill AB252ZD, Scotland. m.greaves@abdn.ac.uk

Current Hematology Reports
|August 23, 2003
PubMed
Summary

Genetic testing for venous thrombosis is costly and often inappropriate. Identifying acquired prothrombotic states like antiphospholipid syndrome, myeloproliferative disorders, and cancer is more beneficial for guiding therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterization and treatment of congenital thrombotic thrombocytopenic purpura.

Blood·2019
Same author

Haemoglobin Titusville: low oxygen saturations but is the patient hypoxaemic?

QJM : monthly journal of the Association of Physicians·2018
Same author

Measurement of rivaroxaban concentrations demonstrates lack of clinical utility of a PT, dPT and APTT test in estimating levels.

International journal of laboratory hematology·2018
Same author

Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura.

Blood·2017
Same author

Hepatitis B serology and DNA detection in multitransfused haemophiliacs and factor VIII and IX concentrates.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

An observational study of direct oral anticoagulant awareness indicating inadequate recognition with potential for patient harm.

Journal of thrombosis and haemostasis : JTH·2016

Area of Science:

  • Hematology
  • Genetics
  • Clinical Medicine

Background:

  • Venous thrombosis has a notable genetic component in many patients.
  • Extensive clinical resources are allocated to investigating genetic causes.
  • Uncritical genetic testing for venous thromboembolism offers limited clinical gains and raises concerns about test appropriateness.

Purpose of the Study:

  • To evaluate the clinical utility of genetic testing versus acquired prothrombotic state identification in venous thrombosis management.
  • To highlight the importance of identifying specific acquired conditions that influence therapeutic decisions.

Main Methods:

  • Review of current clinical practices in venous thrombosis investigation.
  • Analysis of the cost-effectiveness and clinical impact of genetic testing.

Related Experiment Videos

  • Identification and comparison of diagnostic approaches for inherited versus acquired prothrombotic states.

    • Main Results:

    • Genetic testing for venous thrombosis is frequently performed but yields limited therapeutic benefits.
    • Acquired prothrombotic states, including antiphospholipid syndrome, myeloproliferative disorders, and cancer, significantly increase thrombosis risk.
    • Identification of these acquired states is crucial for tailoring patient management and therapy.

    Conclusions:

    • Focusing on acquired prothrombotic states offers greater clinical value than widespread genetic testing for venous thrombosis.
    • Therapeutic decisions in venous thrombosis should prioritize the identification of specific, actionable acquired risk factors.